GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Sun Pharma Advanced Research Co SPARC.NS · INR

Health Care · NSE · 🇮🇳 India

Compare

210.80

+8.93%

Close of 9 Nov 2026, in INR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in INR, from our data supplier.

FY2026

Revenue

₹18.79bn

FY2017FY2026

Net income

₹15.53bn

FY2017FY2026

Free cash flow

−₹2.97bn

FY2017FY2026

Shareholders' equity

₹13.39bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue₹18.79bn₹717.7m₹755.5m₹2.39bn₹1.37bn₹2.53bn₹768.1m₹1.83bn₹782.6m₹1.81bn
Research and development₹226.6m₹813.3m₹4.79bn₹4.53bn₹3.24bn₹3.88bn₹3.87bn₹1.48bn₹3.21bn₹3.04bn
Operating income₹15.89bn−₹3.34bn−₹4.12bn−₹2.24bn−₹1.90bn−₹1.40bn−₹3.15bn−₹1.52bn−₹2.51bn−₹1.31bn
Net income₹15.53bn−₹3.43bn−₹3.87bn−₹2.23bn−₹2.03bn−₹1.51bn−₹3.12bn−₹1.45bn−₹1.97bn−₹1.20bn
Diluted earnings per share47.86-10.55-11.93-6.86-7.01-5.72-11.92-5.55-7.76-4.85

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets₹21.71bn₹3.36bn₹5.15bn₹8.30bn₹2.80bn₹2.30bn₹2.73bn₹3.98bn₹3.09bn₹2.74bn
Cash and short-term investments₹26.2m₹19.6m₹1.57bn₹4.07bn₹128.9m₹157.3m₹88.4m₹2.11bn₹1.09bn₹731.4m
Total liabilities₹8.32bn₹5.52bn₹3.89bn₹3.17bn₹2.49bn₹3.98bn₹2.91bn₹1.02bn₹1.24bn₹1.14bn
Debt₹5.59bn₹2.69bn₹611.5m₹156.7m₹792.2m₹2.36bn₹683.4m₹16.4m₹22.8m₹31.4m
Shareholders' equity₹13.39bn−₹2.17bn₹1.26bn₹5.13bn₹312.3m−₹1.68bn−₹186.4m₹2.96bn₹1.85bn₹1.60bn
Shares outstanding325m325m325m325m290m264m262m262m254m248m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−₹2.73bn−₹3.60bn−₹4.29bn−₹691.2m−₹2.08bn−₹1.52bn−₹2.11bn−₹1.72bn−₹1.83bn−₹1.28bn
Capital spending−₹238.3m−₹103.4m−₹265.1m−₹153.9m−₹326.8m−₹60.0m−₹540.4m−₹129.5m−₹326.3m−₹85.8m
Free cash flow−₹2.97bn−₹3.71bn−₹4.56bn−₹845.1m−₹2.41bn−₹1.58bn−₹2.65bn−₹1.85bn−₹2.15bn−₹1.37bn
Dividends paid———————−₹916.7m——

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₹399.2m₹18.53bn₹84.5m₹78.6m₹96.4m₹271.9m₹149.1m₹128.6m
Operating income−₹362.0m₹17.71bn−₹715.7m−₹682.7m−₹547.6m−₹561.3m−₹766.4m−₹1.06bn
Net income−₹207.8m₹17.61bn−₹804.2m−₹758.5m−₹518.7m−₹597.7m−₹795.1m−₹1.07bn
Diluted earnings per share-0.6454.27-2.48-2.34-1.60-1.84-2.45-3.31
Cash from operations———−₹1.16bn—−₹3.60bn—−₹2.02bn
Capital spending———−₹231.0m—−₹103.0m—−₹35.0m
Free cash flow———−₹1.39bn—−₹3.71bn—−₹2.06bn
Total assets—₹21.71bn—₹3.22bn—₹3.36bn—₹3.21bn
Cash and short-term investments₹11.6m₹26.2m₹9.4m₹30.0m₹19.6m₹19.6m₹60.7m₹60.7m
Debt—₹5.59bn—₹4.17bn—₹2.69bn—₹1.01bn
Shareholders' equity₹13.39bn₹13.39bn−₹3.45bn−₹3.45bn−₹2.17bn−₹2.17bn−₹773.8m−₹773.8m

Financial ratios

Data as of 20 Sept 2026

FY2026FY2025FY2024FY2023FY2022FY2021
Operating margin84.5%-465.0%-544.7%-93.7%-138.5%-55.5%
Net margin82.7%-477.2%-512.6%-93.2%-148.2%-59.7%
Return on equity116.0%157.9%-307.9%-43.4%-651.4%89.8%
Return on assets71.5%-102.1%-75.2%-26.8%-72.6%-65.8%
Free cash flow yield-4.0%-5.6%-6.4%-0.9%-3.1%-2.8%
Revenue growth2518.3%-5.0%-68.4%74.0%-45.7%229.3%
Earnings growth-553.5%-11.5%74.0%9.4%34.6%-51.6%
Current ratio2.47x0.07x1.02x2.54x0.42x0.27x
Debt to equity0.42x-1.21x0.40x0.01x2.46x-1.40x
Equity ratio61.7%-64.7%24.4%61.8%11.1%-73.3%
Interest coverage46.54x-36.92x-243.49x-29.29x-14.26x-13.19x
R&D as a share of sales1.2%113.3%634.5%189.6%236.1%153.4%
Buybacks as a share of market value0.0%0.0%-0.0%-11.9%-9.8%-0.7%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue98.9%49.3%27.8%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin64.3%27.4%10.9%-18.9%
Net margin62.1%26.5%9.3%-17.9%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings3.9-12.7-16.8-41.8-29.7-50.1-16.3-28.1-24.2-104.8
Price to sales3.360.886.239.044.129.966.122.461.069.6

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.